The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2020

Filed:

Oct. 21, 2016
Applicant:

Dragon Victory Development Ltd., Hong Kong, HK;

Inventors:

Cornelia Wing Yin Man, Hong Kong, HK;

Norman Fung Man Wai, Vancouver, CA;

Bing Lou Wong, Irvine, CA (US);

Benjamin Chi Yin Wai, Burnaby, CA;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/573 (2006.01); G01N 33/574 (2006.01); G01N 33/564 (2006.01); G01N 21/64 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57438 (2013.01); G01N 21/6428 (2013.01); G01N 33/564 (2013.01); G01N 2021/6441 (2013.01); G01N 2333/4703 (2013.01); G01N 2333/475 (2013.01); G01N 2333/50 (2013.01); G01N 2333/54 (2013.01); G01N 2333/82 (2013.01); G01N 2333/90283 (2013.01); G01N 2333/9108 (2013.01); G01N 2458/00 (2013.01);
Abstract

Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumour antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods.


Find Patent Forward Citations

Loading…